Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Datopotamab deruxtecan in EGFR-mutated advanced non-small cell lung cancer after osimertinib resistance
NL-OMON59251Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started Nov 2019; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on NL-OMON59251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59251.